Coherus BioSciences, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.120
+0.110 (10.89%)
At close: Apr 17, 2025, 4:00 PM
1.080
-0.040 (-3.57%)
After-hours: Apr 17, 2025, 5:29 PM EDT
Coherus BioSciences Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Coherus BioSciences stock have an average target of 5.38, with a low estimate of 1.50 and a high estimate of 7.00. The average target predicts an increase of 380.36% from the current stock price of 1.12.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 11, 2025.
Analyst Ratings
The average analyst rating for Coherus BioSciences stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +525.00% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +525.00% | Jan 23, 2025 |
| Baird | Baird | Buy Maintains $4 → $6 | Buy | Maintains | $4 → $6 | +435.71% | Dec 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +525.00% | Dec 4, 2024 |
| Baird | Baird | Buy Maintains $8 → $4 | Buy | Maintains | $8 → $4 | +257.14% | Nov 8, 2024 |
Financial Forecast
Revenue This Year
103.75M
from 266.96M
Decreased by -61.14%
Revenue Next Year
113.11M
from 103.75M
Increased by 9.02%
EPS This Year
-1.04
from 0.25
EPS Next Year
-0.73
from -1.04
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 114.5M | 167.0M | 208.0M | ||
| Avg | 103.8M | 113.1M | 128.0M | ||
| Low | 93.1M | 63.7M | 88.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -57.1% | 60.9% | 83.9% | ||
| Avg | -61.1% | 9.0% | 13.1% | ||
| Low | -65.1% | -38.6% | -22.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.72 | 0.07 | -0.32 | ||
| Avg | -1.04 | -0.73 | -0.62 | ||
| Low | -1.20 | -1.13 | -0.81 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.